SCHEMBL19911461

SCHEMBL19911461

Cc1cc2nnn(S(=O)(=O)c3cccnc3)c2cc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 2/20 0.47
TSHR P16473 2/20 0.45
KMT2A Q03164 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ALDH1A1 P00352 1/20 0.43
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
CYP2C19 P33261 1/20 0.40
LMNA P02545 1/20 0.40
NAPRT Q6XQN6 1/20 0.40
NPSR1 Q6W5P4 2/20 0.39
USP2 O75604 1/20 0.39
HTT P42858 1/20 0.39
MGAM O43451 2/20 0.39
AMY1A P0DUB6 2/20 0.39
GAA P10253 2/20 0.39
SI P14410 2/20 0.39
MGAM2 Q2M2H8 2/20 0.39
MAPT P10636 1/20 0.39
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19848122 0.86 SLC9A1 (0.54) SLC9A1TSHRKMT2AHSD17B10ALDH1A1
SCHEMBL19911488 0.86 SLC9A1 (0.54) SLC9A1TSHRKMT2AHSD17B10ALDH1A1
SCHEMBL19848288 0.85 SLC9A1 (0.65) SLC9A1TSHRKMT2AHSD17B10ALDH1A1
SCHEMBL29479890 0.81 SLC9A1 (0.72) SLC9A1TSHRKMT2AHSD17B10ALDH1A1
SCHEMBL4339723 0.81 SLC9A1 (0.72) SLC9A1TSHRKMT2AHSD17B10ALDH1A1
SCHEMBL19911619 0.81 SLC9A1 (0.49) SLC9A1TSHRKMT2AALDH1A1POLB
SCHEMBL19848250 0.81 SLC9A1 (0.49) SLC9A1TSHRKMT2AHSD17B10ALDH1A1
SCHEMBL19848586 0.81 SLC9A1 (0.49) SLC9A1TSHRKMT2AHSD17B10ALDH1A1
SCHEMBL19848386 0.81 SLC9A1 (0.49) SLC9A1KMT2APOLBCYP2C19NAPRT
SCHEMBL19848252 0.80 SMN1; SMN2 (0.52) SLC9A1TSHRKMT2AHSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery BPTF, BRD4, KCNN2 SLC9A1 341/4885TSHR 2034/4885KMT2A 458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.